John Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. He currently serves on the boards of directors of Neos Therapeutics, Inc., Xeris Pharmaceuticals, Inc., Forge Therapeutics, Inc., and Patara Pharma, Inc. and chairman of the board of directors of Speak, Inc. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.